Dimensional Fund Advisors LP lessened its stake in shares of DaVita Inc. (NYSE:DVA – Get Rating) by 4.4% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 1,142,535 shares of the company’s stock after selling 52,813 shares during the period. Dimensional Fund Advisors LP owned about 1.27% of DaVita worth $85,315,000 at the end of the most recent reporting period.
Several other large investors have also modified their holdings of DVA. Raymond James & Associates increased its stake in DaVita by 4.0% in the 1st quarter. Raymond James & Associates now owns 22,651 shares of the company’s stock worth $2,562,000 after purchasing an additional 865 shares in the last quarter. American Century Companies Inc. raised its holdings in shares of DaVita by 37.4% during the first quarter. American Century Companies Inc. now owns 6,555 shares of the company’s stock valued at $741,000 after acquiring an additional 1,785 shares during the period. US Bancorp DE lifted its position in shares of DaVita by 63.6% in the 1st quarter. US Bancorp DE now owns 2,998 shares of the company’s stock valued at $338,000 after acquiring an additional 1,166 shares in the last quarter. Cambridge Investment Research Advisors Inc. boosted its stake in DaVita by 7.3% in the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 3,551 shares of the company’s stock worth $402,000 after purchasing an additional 242 shares during the period. Finally, Healthcare of Ontario Pension Plan Trust Fund grew its position in DaVita by 847.8% during the 1st quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 1,090 shares of the company’s stock worth $123,000 after purchasing an additional 975 shares in the last quarter. 86.52% of the stock is owned by institutional investors.
DaVita Price Performance
Shares of NYSE:DVA opened at $96.94 on Wednesday. The stock has a market capitalization of $8.79 billion, a P/E ratio of 17.89, a P/E/G ratio of 1.02 and a beta of 0.93. The business has a 50-day moving average of $86.24 and a two-hundred day moving average of $80.33. DaVita Inc. has a fifty-two week low of $65.28 and a fifty-two week high of $103.00. The company has a debt-to-equity ratio of 8.25, a current ratio of 1.18 and a quick ratio of 1.14.
Insider Buying and Selling
In related news, CEO Javier Rodriguez sold 16,916 shares of DaVita stock in a transaction on Wednesday, May 10th. The shares were sold at an average price of $99.44, for a total value of $1,682,127.04. Following the transaction, the chief executive officer now owns 315,622 shares in the company, valued at approximately $31,385,451.68. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, Director Barbara J. Desoer sold 2,449 shares of the firm’s stock in a transaction on Wednesday, May 10th. The shares were sold at an average price of $101.61, for a total value of $248,842.89. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CEO Javier Rodriguez sold 16,916 shares of the stock in a transaction on Wednesday, May 10th. The shares were sold at an average price of $99.44, for a total transaction of $1,682,127.04. Following the completion of the sale, the chief executive officer now directly owns 315,622 shares of the company’s stock, valued at $31,385,451.68. The disclosure for this sale can be found here. In the last three months, insiders sold 39,668 shares of company stock valued at $3,889,765. Company insiders own 1.00% of the company’s stock.
Analysts Set New Price Targets
Several analysts have recently commented on DVA shares. UBS Group raised their target price on DaVita from $91.00 to $100.00 in a research report on Tuesday, May 9th. Truist Financial upped their target price on DaVita from $90.00 to $100.00 in a report on Tuesday, May 9th. StockNews.com initiated coverage on shares of DaVita in a report on Thursday, May 18th. They set a “buy” rating for the company. TheStreet upgraded shares of DaVita from a “c” rating to a “b-” rating in a research note on Monday, May 8th. Finally, Bank of America lifted their target price on shares of DaVita from $86.00 to $96.00 in a research note on Tuesday, May 9th. One analyst has rated the stock with a sell rating, five have issued a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $96.88.
DaVita, Inc engages in the provision of medical care services. It operates through the following two segments: US Dialysis and Related Lab Services, and Other-Ancillary Services and Strategic Initiatives. The US Dialysis and Related Lab Services segment offers kidney dialysis services in the United States for patients suffering from chronic kidney failure.
- Get a free copy of the StockNews.com research report on DaVita (DVA)
- Airline ETFs: What They Are and How to Invest
- Williams-Sonoma Is The Retail Value Play, Here’s Why
- Ladder Corporation: Climbing Higher And Paying 9% Yield
- Microbot Medical spikes 150% on its Endovascular Surgical Robot
- PetMed Express: Charts Say This Could Be The Bottom
Receive News & Ratings for DaVita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DaVita and related companies with MarketBeat.com's FREE daily email newsletter.